1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 34 pages

Summary

Table of Contents

Search Inside

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Integrated BioTherapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Integrated BioTherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Integrated BioTherapeutics, Inc.
- The report provides overview of Integrated BioTherapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Integrated BioTherapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Integrated BioTherapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Integrated BioTherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Integrated BioTherapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrated BioTherapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review

Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • January 2017
  • by GlobalData

Summary Protalix BioTherapeutics, Inc. (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s pipeline products include PRX-102, a ...

Northwest Biotherapeutics Inc (NWBO) - Medical Equipment - Deals and Alliances Profile

Northwest Biotherapeutics Inc (NWBO) - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • Company report
  • April 2017
  • by GlobalData

Summary Northwest Biotherapeutics Inc (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer in an effective way without toxicities associated ...

Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • April 2017
  • by GlobalData

Summary Atara Biotherapeutics Inc (Atara) is a clinical-stage biopharmaceutical company that develops therapies for medical needs. The company develops drugs for muscle wasting conditions and cancer. Its ...

Eleven Biotherapeutics Inc

December 2016 $ 99

Northwest Biotherapeutics, Inc.

February 2017 $ 99

Asterias Biotherapeutics Inc

December 2016 $ 99

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.